Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
August 9, 2018 11:22 AM EDTCantor Fitzgerald analsyt Louise Chen remains positive on Perrigo Co. (NYSE: PRGO) despite lowered FY18 guidance.
Chen notes weakness was driven by headwinds in its Rx business, which it now expects to sell, merge or separate out in 2H19.... More
